These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2811893)

  • 1. "On-off"-induced lethal hyperthermia.
    Pfeiffer RF; Sucha EL
    Mov Disord; 1989; 4(4):338-41. PubMed ID: 2811893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
    Douglas A; Morris J
    Age Ageing; 2006 Nov; 35(6):640-1. PubMed ID: 16943262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome and acute motor axonal neuropathy after Campylobacter jejuni infection.
    Rajabally YA; Ramlackhansingh A; Fraser M; Abbott RJ
    Neurophysiol Clin; 2009 Aug; 39(3):135-8. PubMed ID: 19716463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation].
    Osoegawa M; Motomura S; Yamanaka H; Tamura K; Miyoshi T
    Rinsho Shinkeigaku; 1999 Jun; 39(6):653-7. PubMed ID: 10502992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Akinetic crisis in Parkinson disease].
    Bächli E; Albani C
    Schweiz Med Wochenschr; 1994 Jun; 124(23):1017-23. PubMed ID: 8023100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of levodopa on word intelligibility in Parkinson's disease.
    De Letter M; Santens P; Van Borsel J
    J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain intensity on and off levodopa in patients with Parkinson's disease.
    Nebe A; Ebersbach G
    Mov Disord; 2009 Jun; 24(8):1233-7. PubMed ID: 19412949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disturbance of micturition in Parkinson's disease].
    Sakakibara R; Uchiyama T; Yoshiyama M; Hattori T
    No To Shinkei; 2001 Nov; 53(11):1009-14. PubMed ID: 11761908
    [No Abstract]   [Full Text] [Related]  

  • 14. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Initial management and adaptation of Parkinson's disease treatment].
    Gérard JM
    Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacotherapy of a geriatric patient with Parkinson's disease].
    Klemmer JM; Schmitz S; Roth S; Simons S; Reineking N; Eisert A; Lang B; Jaehde U
    Med Monatsschr Pharm; 2007 Nov; 30(11):411-4. PubMed ID: 18062332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug for "off" episodes of Parkinson's--effective but limited.
    Mayo Clin Health Lett; 2005 Jul; 23(7):4. PubMed ID: 16189845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.